JHJeffrey B. Hoag

Jeffrey B. Hoag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey B. Hoag has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Aimel Azizi

    Drexel University College of Medicine, Philadelphia, PA, USA

    1 shared publication
  • Brett A. Simon

    Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University Baltimore, MD

    1 shared publication
  • Christian A. Merlo

    Department of Medicine , The Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

    1 shared publication
  • Douglas Reh

    Department of Otolaryngology , The Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

    1 shared publication
  • Hamid Rabb

    Departments of 1Medicine, Anesthesiology and 2Critical Care Medicine, 3Surgery and 4Pathology, The Johns Hopkins University, Baltimore, Maryland

    1 shared publication
  • Heitham Hassoun

    Departments of 1Medicine, Anesthesiology and 2Critical Care Medicine, 3Surgery and 4Pathology, The Johns Hopkins University, Baltimore, Maryland

    1 shared publication

Latest Publications

  • A Comprehensive Review of Spontaneous Pneumothorax Complicating Sarcoma

    by Jeffrey B. Hoag, Michael Sherman, Quadeer Fasihuddin, Mark E. Lund


  • Top Cited Papers

    An epistaxis severity score for hereditary hemorrhagic telangiectasia

    by Jeffrey B. Hoag, Peter Terry, Sally Mitchell, Douglas Reh, Christian A. Merlo

    Objectives/Hypothesis: Hereditary hemorrhagic telangiectasia (HHT)‐related epistaxis leads to alterations in social functioning and quality of life. Although more than 95% experience epistaxis, there is considerable variability of severity. Because no standardized method exists to measure epistaxis severity, the purpose of this study was to determine factors associated with patient‐reported severity to develop a severity score.Study Design: Prospective, survey‐based study.Methods: HHT care providers and a focus group of patients were interviewed to determine epistaxis‐associated factors. From this, an electronic survey was developed and administered to patients with HHT. Descriptive analyses were performed with calculations of means and medians for continuous and proportions for categorical variables. Multiple ordinal logistic and linear regression models were developed to determine risk factors for epistaxis severity.Results: Nine hundred respondents from 21 countries were included. Eight hundred fifty‐five (95%) subjects reported epistaxis. The mean (standard deviation) age was 52.1 (13.9) years, and 61.4% were female. Independently associated risk factors for self‐reported epistaxis severity included epistaxis frequency (odds ratio [OR] 1.57), duration (OR 2.17), intensity (OR 2.45), need for transfusion (OR 2.74), anemia (OR 1.44), and aggressiveness of treatment required (OR 1.53, P < .001 for all).Conclusions: Risk factors for increasing epistaxis severity in patients with HHT include frequency, duration, and intensity of episodes; invasiveness of prior therapy required to stop epistaxis; anemia; and the need for blood transfusion. From these factors, an epistaxis severity score will be presented. Laryngoscope, 2010


  • Open Access

    Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

    by Jeffrey B Hoag, Aimel Azizi, Timothy J Doherty, Jason Lu, Rudolph E Willis, Mark E Lund

    Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck, and non-small cell lung cancer. However, due to the relatively recent addition of biologic compounds to the therapeutic arsenal, information related to adverse reactions is less well known than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated as the most frequent side effect cited during cetuximab therapy for malignancy; however, other effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead to significant morbidity and mortality. The purpose of this review is to compile the various pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to compare the incidence of these adverse reactions to standard therapies.


  • Effects of acid aspiration-induced acute lung injury on kidney function

    by Jeffrey B. Hoag, Manchang Liu, R. Blaine Easley, Martin F. Britos-Bray, Priya Kesari, Heitham Hassoun, Mark Haas, Rubin M. Tuder, Hamid Rabb, Brett A. Simon

    Acute lung injury (ALI) in combination with acute kidney injury carries a mortality approaching 80% in the intensive care unit. Recently, attention has focused on the interaction of the lung and kidney in the setting of ALI and mechanical ventilation (MV). Small animal models of ALI and MV have demonstrated changes in inflammatory mediators, water channels, apoptosis, and function in the kidney early in the course of injury. The purpose of this investigation was to test the hypothesis that ALI and injurious MV cause early, measurable changes in kidney structure and function in a canine HCl aspiration model of ALI when hemodynamics and arterial blood gas tensions are carefully controlled. Intratracheal HCl induced profound ALI as demonstrated by increased shunt fraction and airway pressures compared with sham injury. Sham-injured animals had similar mean arterial pressure and arterial Pco2 and HCO3 levels compared with injured animals. Measurements of renal function including renal blood flow, urine flow, serum creatinine, glomerular filtration rate, urine albumin-to-creatinine ratio, and kidney histology scores were not different between groups. With maintenance of hemodynamic parameters and alveolar ventilation, ALI and injurious MV do not alter kidney structure and function early in the course of injury in this acid aspiration canine model. Kidney injury in large animal models may be more similar to humans and may differ from results seen in small animal models.